Home/Filings/4/0001209191-24-004439
4//SEC Filing

Gaiero David G 4

Accession 0001209191-24-004439

CIK 0001662244other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 6:11 PM ET

Size

15.0 KB

Accession

0001209191-24-004439

Insider Transaction Report

Form 4
Period: 2024-02-29
Gaiero David G
Vice President, Finance
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-29$1.68/sh+3,239$5,44295,272 total
  • Exercise/Conversion

    Common Stock

    2024-02-29$1.69/sh+4,746$8,021100,018 total
  • Exercise/Conversion

    Common Stock

    2024-03-04$1.69/sh+2,373$4,010102,391 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-02-293,23916,196 total
    Exercise: $1.68Exp: 2030-12-10Common Stock (3,239 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-02-294,74685,425 total
    Exercise: $1.69Exp: 2033-02-03Common Stock (4,746 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-03-042,37383,052 total
    Exercise: $1.69Exp: 2033-02-03Common Stock (2,373 underlying)
Footnotes (2)
  • [F1]The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
  • [F2]The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Issuer

Cyteir Therapeutics, Inc.

CIK 0001662244

Entity typeother

Related Parties

1
  • filerCIK 0001799784

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 6:11 PM ET
Size
15.0 KB